Analysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Target Price at $21.00

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $21.00.

A number of brokerages have commented on TLX. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st.

Telix Pharmaceuticals Trading Down 1.8%

TLX opened at $6.42 on Friday. The company has a 50 day moving average of $7.66 and a two-hundred day moving average of $9.35. Telix Pharmaceuticals has a 52-week low of $6.28 and a 52-week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $217,000. JPMorgan Chase & Co. acquired a new position in Telix Pharmaceuticals in the third quarter worth about $243,000. Finally, Mariner LLC acquired a new stake in Telix Pharmaceuticals during the fourth quarter valued at approximately $274,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.